H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme (HALO) to $75 from $72 and keeps a Buy rating on the shares following the Q2 report. The company increased its fiscal 2025 guidance for the third time this year after reporting another robust quarter, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme upgraded to Overweight from Equal Weight at Morgan Stanley
- Halozyme Therapeutics Reports Strong Q2 2025 Results
- Positive Outlook and Strong Performance Drive Buy Rating for Halozyme
- Halozyme reports Q2 non-GAAP EPS $1.54, consensus $1.23
- Halozyme raises FY25 non-GAAP EPS view to $6.00-$6.40 from $5.30-$5.70